Axon Enterprise, Inc. (AXON) develops hardware and software solutions for public safety and security. While many investors first recognize the company through its TASER brand of conducted energy devices, Axon has grown into a broader platform that includes body cameras, cloud-based evidence management, drones, and artificial intelligence. I follow the company closely because of its strong position in U.S. public safety technology and the increasing share of recurring, subscription-style revenue.
Axon traces its roots to 1993, when Rick Smith and his brother Tom Smith founded the company—then called AIR TASER, later TASER International—in Scottsdale, Arizona. It went public in 2001 and adopted the Axon Enterprise name in 2017, reflecting a shift from hardware-focused energy weapons toward an integrated, software-driven public safety platform. The company remains headquartered in Scottsdale, Arizona, with Rick Smith as chief executive officer.
Axon combines connected hardware with cloud software. Its Connected Devices segment includes TASER conducted energy weapons, body-worn cameras, in-car cameras, drones, counter-drone technology, and accessories. The Software and Services segment delivers cloud-based, software-as-a-service offerings such as the Evidence.com digital evidence management platform, productivity tools, real-time operations software, and AI-powered applications like automated report writing. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The company often pairs hardware sales with multi-year subscription plans, which supports recurring revenue and strengthens customer ties. This approach has increased the proportion of high-margin, recurring software and services revenue, while the TASER brand continues to serve as an entry point for new customers.
Axon’s portfolio centers on its mission to “protect life.” The TASER line of conducted energy devices remains its most recognizable offering, providing law enforcement with a less-lethal alternative to firearms. The company also supplies body cameras, in-car video systems, and drone and counter-drone capabilities. On the software side, Evidence.com acts as a central hub for storing, managing, and sharing digital evidence, with added tools for records management, real-time awareness, and AI-assisted report drafting.
Axon sells primarily through a direct sales force and online store, supplemented by distribution partners. It holds a leading position in U.S. law enforcement for body cameras and conducted energy weapons. Its main competitor is Motorola Solutions, which operates across similar software and hardware categories. Axon differentiates itself through its integrated hardware-and-software ecosystem, which can raise switching costs for customers.
Investors pay attention to Axon for several structural reasons. The company maintains a large installed base among U.S. police agencies, creating a stable customer foundation. Its subscription-based software and services provide more predictable revenue than one-time hardware sales. Axon is also expanding beyond traditional law enforcement into federal, military, private security, and enterprise markets, as well as newer areas such as drones and counter-drone technology.
Innovation in artificial intelligence and real-time operations software represents another area of focus, as these capabilities can enhance platform value and support additional subscriptions. The company’s long-term goal of reducing gun-related deaths between police and the public continues to guide its product development.
Several factors warrant attention. Public-sector budgeting can fluctuate with economic conditions and government priorities. Products face ongoing regulatory and public scrutiny, including debates around conducted energy weapons, surveillance technologies, and data-privacy issues. Competition from larger players such as Motorola Solutions remains significant, and expansion into drones and AI carries execution risk. The stock’s valuation has historically priced in strong growth, making it sensitive to shifts in sentiment. Supply-chain and acquisition integration risks also apply, as with many technology companies.
I often rely on Tickeron’s AI Screener to quickly filter stocks by technical indicators, fundamentals, and industry patterns. It helps surface ideas that align with my own criteria without spending hours on manual screening, which keeps my research process more efficient.
Axon Enterprise has evolved from a conducted energy weapons manufacturer into an integrated public safety technology platform that blends connected devices with a growing cloud software and AI ecosystem. Its established presence in law enforcement, expanding recurring revenue base, and entry into new security markets position it as a notable player in the sector. As with any growth-oriented technology stock, long-term success will depend on continued innovation, effective management of regulatory and competitive pressures, and the ability to convert hardware customers into ongoing software subscribers.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
Following a +1.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where AXON advanced for three days, in 273 of 370 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
AXON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AXON as a result. In 49 of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 65%.
The Moving Average Convergence Divergence Histogram (MACD) for AXON turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In 27 of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at 71%.
The 50-day moving average for AXON moved below the 200-day moving average on October 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
The Aroon Indicator for AXON entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. AXON’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 79 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 82 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AXON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 78, placing this stock worse than average.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.920) is normal, around the industry mean (5.050). AXON has a moderately high P/E Ratio (126.721) as compared to the industry average of (17.247). Projected Growth (PEG Ratio) (1.949) is also within normal values, averaging (3.110). Dividend Yield (0.000) settles around the average of (0.055) among similar stocks. P/S Ratio (12.034) is also within normal values, averaging (18.367).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a clinical-stage biopharmaceutical company
Industry AerospaceDefense